- 삼성바이오로직스 보관

Samsung Biologics Stock Falls On Sentiment: Strong Margins

Samsung Biologics stays Buy despite labor and sentiment risks; revenue and net income surged, margins remain exceptional, and analysts see upside to the average target.

2026년 11월 13일

English

Samsung Biologics Q2 Revenue Rises: What to Watch Next

Samsung Biologics holds strong growth and margins, with analysts rating it Buy, but labor and governance risks could hurt operating profit conversion, so upside depends on margin stability.

2026년 10월 21일

English

Samsung Biologics Q2 Earnings Climb – More Upside Than Valuation Signals

Samsung Biologics has Buy consensus and strong results: revenue up 30%, operating profit up 23%, net income up 33%, with margins at 54% gross and 44% operating, while the stock trades below the average target of about 1.97M won.

2026년 10월 01일

English

삼성바이오로직스 실적 분석 주가 전망과 투자 전략

삼성바이오로직스는 고성장과 고마진이 확인되어 투자의견 매수, 평균 목표주가 197만6천원으로 업사이드는 약 38%이나 마진 변동 리스크는 있음

2026년 10월 01일

Korean

Samsung Biologics Earnings Rally – Growth and Profit Insight

Samsung Biologics has strong growth and high margins; analysts rate it a Buy with upside, but labor and production disruption risks keep volatility high.

2026년 08월 26일

English

삼성바이오로직스 실적 분석과 주가 전망 투자 전략

삼성바이오로직스 매수 의견으로 실적은 매출과 영업이익이 고성장과 고마진을 유지하나, 생산차질과 규제노무 리스크가 변동성을 좌우함

2026년 08월 26일

Korean

Samsung Biologics Stock Gains Momentum – Higher Upside Outlook

Samsung Biologics has strong fundamentals with 25.8% YoY revenue and 35% YoY operating profit, elite margins, and a Strong Buy consensus, but the stock is discounted due to manufacturing continuity and labor legal risks.